書誌事項
- タイトル別名
-
- Clinical study of sitafloxacin in the treatment of male gonococcal urethritis
この論文をさがす
抄録
The clinical efficacy and safety of sitafloxacin (STFX), a new quinolone compound, were evaluated in male patients with gonococcal urethritis by preliminary study. STFX was orally administered at a single dose of 200 mg. Clinical efficacy was evaluated based on the criteria for evaluation of clinical efficacy of antimicrobial agents on urinary tract infection (draft, fourth edition).<BR>Overall clinical efficacy was 75.0%(9/12) in gonococcal urethritis. The range of MICs of STFX against 12 Neisseria gonorrhoeae isolates from this study was≤0.001 to 0.25μg/mL, and MICs of 3 isolates were 0.25μg/mL. Overall eradication was 75.0%(9/12) for N. gonorrhoeae. Eradication by MICs was 100%(8/8) with MIC of≤0.06 p emL, and 25.0%(1/4) with MIC of≤0.12μg/mL.<BR>MICs of ciprofloxacin against 7 of 12 isolates were≤1μg/mL. These 7 isolates had amino acid substitutions in quinolone-resistance-determining regions of GyrA and ParC. Four of 7 strains with quinolone resistance were eradicated. Adverse reactions occurred in 25.0%(3/12) of cases evaluable for safety. Adverse reactions involved diarrhea, headache, and blood bilirubin increase in one case each. All symptoms were mild.<BR>Results suggest that STFX at a single dose of 200 mg is inadequate in dosage for eradicating quinoloneresistant N. gonorrhoeae, but safe in the treatment of male gonococcal urethritis.
収録刊行物
-
- 日本化学療法学会雑誌
-
日本化学療法学会雑誌 56 (Supplement1), 146-153, 2008
公益社団法人 日本化学療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001206288104832
-
- NII論文ID
- 10021192922
- 130004102781
-
- NII書誌ID
- AN10472127
-
- ISSN
- 18845886
- 13407007
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可